Ovarian Cancer Trial, Recruiting NCT06115122 Sponsor: Oulu University Hospital Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06115122
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Mothers (PEPPI study)

  • Women who are in the first trimester of pregnancy
  • Women who are able to understand Finnish
  • Women who are 18 years of age or older
  • Women who have signed a consent form agreeing to take part

Mothers (FERPPI study — additional criteria)

  • Mothers who are already taking part in the PEPPI study
  • Mothers who have blood samples taken in both the first and third trimesters of pregnancy
  • Mothers who agree to allow a blood sample to be taken from the umbilical cord after the baby is born

Fathers

  • The biological father of a child whose mother took part in the PEPPI study
  • Men who are 18 years of age or older
  • Men who have signed a consent form agreeing to take part
  • Men who are able to understand Finnish

Children (PEPPI study)

  • Children born to a mother who took part in the PEPPI study
  • Children whose parent or parents have signed a consent form

Children (PEPPI-offspring study)

  • Children whose mother was in the risk, control, or PCOS group during the PEPPI study and had an ultrasound between weeks 30–32 of pregnancy, or whose mother developed pre-eclampsia during the pregnancy regardless of which group she was in (confirm with trial site)
  • Children whose parent or parents agree to participation

Children (FERPPI study)

  • Children whose parent or parents have signed a consent form
  • Children whose mother had blood samples taken in both the first and third trimesters of pregnancy
  • Children who have blood samples taken at birth and again at 3 months of age

Who may not be able to join:

Mothers (PEPPI study)

  • Women who are carrying more than one baby (e.g., twins or more)
  • Women whose pregnancy ends in miscarriage or termination
  • Women who do not have a blood sample taken in the first trimester

Mothers (FERPPI study)

  • Mothers who do not have blood samples from both the first and third trimesters
  • Mothers who do not have an umbilical cord blood sample collected after the birth

Fathers

  • Men who are not able to understand Finnish

Children (PEPPI study)

  • Children whose parent or parents have not given consent for them to participate

Children (PEPPI-offspring study)

  • Children whose mother or father declines participation

Children (FERPPI study)

  • Children whose parent or parents have not given consent
  • Children whose mother does not have the required blood samples
  • Children who do not have blood samples taken at the required times

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jaana Nevalainen, Assoc prof, The Wellbeing Services County of North Ostrobothnia

Phone: +358405801857

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Oulu University Hospital
Registry
ClinicalTrials.gov
Start date
15 February 2022
Est. completion
31 December 2027

Where this trial is recruiting

🇫🇮 Finland

Primary endpoints

Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate; Severe Hypertension; Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels; Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia; Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level; Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure; Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32-34-37 Weeks of Gestation Owing to Hypertension-related...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov